Gilead Sciences Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
Rapid Read

Gilead Sciences Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing

What's Happening? Gilead Sciences, Inc. has announced royalty-free voluntary licensing agreements with three generic manufacturers to facilitate future access to its investigational antiviral, obeldesivir, for post-exposure prophylaxis (PEP) of Ebola Bundibugyo virus disease (BVD). These agreements
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.